At the news
? BULLISHIMPACT 5/10 8-K filed Jun 16, 2026 at 09:05 ET
Oncolytics Biotech announced the USPTO issued a new patent protecting the commercial manufacturing process of its lead asset pelareorep through 2044, plus a pending method-of-use application that could extend protection to 2046. This strengthens the company's IP moat but does not alter near-term clinical or financial trajectory for this pre-revenue biotech.
- USPTO issued a new patent covering pelareorep's proprietary manufacturing process, with protection expected into 2044.
- A previously filed method-of-use patent application remains under review and, if issued, would provide protection into 2046.
- Oncolytics plans to file additional patent applications in 2026 to further expand the pelareorep IP estate.
- The company is a clinical-stage biotech with no approved products or reported revenue.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access